Blog
RSS FeedPosted by Michael Wonder on 11 Oct 2022
New generation of weight loss medications offer promise — but at a price
11 October 2022 - Excitement is building about a new generation of drugs that tout the ability to help adults ...
Posted by Michael Wonder on 11 Oct 2022
ICER releases draft evidence report on treatment for vasomotor symptoms associated with menopause
11 October 2022 - Registration now open for October 19 “Early Insights” webinar. ...
Posted by Michael Wonder on 05 Oct 2022
ICER to assess treatments for non-alcoholic steatohepatitis
5 October 2022 - Report will be subject of Midwest CEPAC meeting in April 2023; Draft Scoping Document open to ...
Posted by Michael Wonder on 04 Oct 2022
Newly approved ALS drug Relyvrio to face its next challenge: pricing and reimbursement
4 October 2022 - There’s a swirl of controversy surrounding last week’s regulatory approval of Relyvrio (sodium phenylbutyrate and taurursodiol), which ...
Posted by Michael Wonder on 13 Sep 2022
ICER publishes final evidence report and policy recommendations on treatments for amyotrophic lateral sclerosis
13 September 2022 - Majority of independent appraisal committee voted that evidence is adequate to demonstrate that both AMX0035 and oral ...
Posted by Michael Wonder on 31 Aug 2022
ICER publishes evidence report on treatments for obesity management
31 August 2022 - Greater weight loss was seen with semaglutide and with phentermine/topiramate; less weight loss was seen with liraglutide ...
Posted by Michael Wonder on 04 Aug 2022
ICER publishes evidence report on treatments for amyotrophic lateral sclerosis
4 August 2022 - Given current data, AMX0035 is comparable or better to standard of care; AMX0035 would achieve common thresholds ...
Posted by Michael Wonder on 14 Jun 2022
ICER releases draft evidence report on treatments for amyotrophic lateral sclerosis
14 June 2022 - Public comment period now open until 13 July 2022; requests to make oral comment during public ...
Posted by Michael Wonder on 01 Jun 2022
ICER to assess treatment for vasomotor symptoms associated with menopause
1 June 2022 - Report will be subject of Midwest CEPAC meeting in December 2022; draft scoping document open to ...
Posted by Michael Wonder on 10 May 2022
ICER publishes final evidence report and policy recommendations on outpatient treatments for COVID-19
10 May 2022 - Independent appraisal committee votes 11-2 that the evidence is not adequate to demonstrate a net health benefit ...
Posted by Michael Wonder on 21 Apr 2022
ICER to assess treatments for multiple sclerosis
21 April 2022 - Report will be subject of New England CEPAC meeting in January 2023; draft scoping document open ...
Posted by Michael Wonder on 14 Apr 2022
ICER publishes 2022 research protocol for assessing unsupported price increases on prescription drugs
14 April 2022 - Final assessment to be published on 6 December 2022. ...
Posted by Michael Wonder on 28 Mar 2022
ICER publishes evidence report on treatments for COVID-19
28 March 2022 - Current evidence suggests all four drugs under review have prices reasonably aligned with patient benefits. ...
Posted by Michael Wonder on 17 Mar 2022
ICER publishes evidence report on novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects
17 March 2022 - Due to the FDA action on plinabulin, ICER will not hold a public meeting but has produced ...
Posted by Michael Wonder on 16 Mar 2022
ICER publishes research protocol for assessing price increases of prescription drugs in California
16 March 2022 - Final assessment to be published on 13 October; drugs to be evaluated are those identified through California’s ...